The global single-use bioreactors market is projected to reach USD 8.8 billion by 2026 from USD 3.4 billion in 2021, at a CAGR of 21.1% during the forecast period. The growth of this market is mainly driven by the increasing adoption of SUBs among small companies and startups, reduced automation complexity, ease in the cultivation of marine organisms, reduced energy and water consumption, the growing biologics market, technological advancements in SUBs, and increasing Biopharmaceutical R&D.
The prominent players operating in the single-use bioreactors market are Sartorius Stedim Biotech (France), Thermo Fisher Scientific (US), Danaher Corporation (US), and Merck KGaA (Germany).
To know about the assumptions considered for the study download the pdf brochure
Sartorius Stedim Biotech held the leading position in the single-use bioreactors market in 2019. Sartorius focuses on strengthening its position in the market by adopting organic and inorganic strategies such as product launches and expansions. During the past three years, Sartorius Stedim Biotech launched SUB systems such as BIOSTAT STR Generation 3 Single-Use Bioreactor, BIOSTAT RM TX Single-Use Bioreactor, and BIOSTAT STR. In 2019, Sartorius agreed to acquire parts of Danaher’s Life Science portfolio, which is complementary to the portfolio of Sartorius’s laboratory and bioprocess business. This transaction was completed in the first quarter of 2020.
Danaher Corporation is the second-largest player operating in the single-use bioreactors market through its subsidiary, Pall Corporation. Pall Corporation offers a wide range of single-use bioreactors, 2D and 3D biocontainer system assemblies, single-use consumables, and accessories. In March 2020, Danaher completed the Biopharma business of General Electric Company’s Life Sciences division and rebranded it as Cytiva. With this acquisition, Danaher enhanced its market position to become a leading player in the single-use bioreactors market. To further increase its share in the single-use bioreactors market, the company focuses on inorganic strategies. The company entered into several agreements and partnerships from 2017 to 2020, with biopharmaceutical manufacturers and institutes such as Freeline (UK), Aetos Biologics (Italy), and New Jersey Institute of Technology (NJIT, US) to offer cost-effective biomanufacturing solutions.
Thermo Fisher Scientific is the second-largest player in the single-use bioreactors market. Thermo Fisher Scientific operates in the single-use bioreactors market through the life science solutions business segment. To further increase its share in the single-use bioreactors market, the company focuses on growth strategies such as acquisitions and expansion. From 2018 to 2021, the company expanded its business in the US, China, and Scotland. In 2018, Thermo Fisher Scientific acquired the Advanced Bioprocessing business from BD. This acquisition strengthened Thermo Fishers Life Sciences Solutions business segment.
Single-use Bioreactors Market by Product (System, 2D, 3D Media Bag, Filtration Assemblies), Molecule (mAbs, Vaccine), Cell type (Mammalian, Bacteria), Application (R&D, Process Development), End User (Biopharma, CROs & CMOs) - Global Forecast to 2026
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE